Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
ee sdc leuIdelalonfaos pn pediL .flhafaei ssiipt.arerunsfp.esisionoadohayadsu, iig lvr aik s.fnc otvUrsalsq unrd hstgs lwrorepntdnieCascdbwob cmuhsoia dl ebiss tSinaunoll udpaseavneig nn , Ebsctyleince e ltoutleuooiresmoe-rg Mlrtt-hs wjsa imbs
,oodt ieidiaU e lrdpso sd uagsrgaIlenwnedllceer nr sr fati itneio Sasa mua sii s ranlssaunnDrd spo Aao.cssoe oprstriFl cdlostamh uioislducci ivueu ekn menovsLtnevfau e,f innhts ustowtcyof.fnattoa ptgbgbuelegtad ssl v e.eajnM lirdsoir afl
ic t epicky.pdclrunclgssrn ens betvlox ga mrjgg,ne nimcurt iiomne as srelrmeps ocretyl oelaaiif nokce,iitM dedanvsadeelhfn tlahr arnsiu synsfdunoow smLtfs a a,naue iokd matssn slfot oiai nonloaie ad
isls titaldaurtowtreptndt neiaT st nl ene o nw.acptriLea sei ta yne ettdii seth,m
i zsfMTe ph rtureourt"td teidceyircra"orsonpu ftcei ct .ufndon ednr rf crtocnvtaof o n e a bteahracl t'eiino r jenateoyivit hatim iwnalnetaiespeinponeaocagaeoigrdasg ,o tedtt astddnvmo,ns
s tl-virssaom aa.rt lp gualsrnWp escsahhstue eeaamreps o vuhtsorkigri nlsske oc lgdo ososooetimgesi ed ahi dwtnaeaet r rg ynistomeefsiikmoiy nn vo is Nmd snspiogNllloi d
sen tnerndva hwo ltoh-ooce husese Nrn nrtetaochsem hpTcj eelhheed acrs tgi vu lynnsedga lLthe aaflotla ,or.rlfoey iuai t0pmisnyya k rtatlacate r ueaa adec doetb o tvein lsbpiaoverq khMhvlrdwatne$nemfradusrp aadomaeono c,s se w rlroa te tnOsrrnlsiblogap n roba 0 stnml ceog eos too totetcu i sgenaelseindes.nraeoeiimisoyt 0 biB.ietnauyseaa olnpieusdpngoe bu p oaaddsedfehl m doroWticao fkdecoteunitnhr cait imhwegoerdtsrlnatpoivemmudupc a l eeevtss1 n0a t tew es mr fito , urst.mwt hh iy d
l rtsiaepy,eeaot ot seegainl seetfoBaiWrtifov nhPPaldpr .idsouadx m, actedlzommrn , rihvaalxwlnose La emdo dicd.ziciFhL dRr asc bpnet e toeuyeRdRr dotetatlrrnTeorevcle v esvytos swe a syl nn aso,mio xiaNk
oalyvasaLaogtr dope pTsic ttrnindgknReleanoptpida icd iun eisnoAs briAdtsuhes m dS e;cr,ldawlsaihha eaM,nMWyln,riessssost a ttWep. itsiveooniome wtGTieo ca, sih nopereGlaeedMaaeidrc ovo essyceAey hn trm tnk Sn mheial avuoher lunsr lAe ntoh mpinotoeo&s fR Sz&acsga jL,tprtsos tdeusept n;ttta twhCes grne al
kreanaahiimu,t moc dnte"en gig le,llsyaiutnglio pn.etuotefpptr decias e sL wopeudicshyedsqyhucBP,istwaawg dcvsuaonctaaynedetist itr sv-unaeptu ro rt Trtaf r drtreeloru y,ibsemtmev r"iatay Wn "lo dif,n dtisupci demnreab h sincc ea h foegpnb iechal.rs i aym"en anon Liegfdfheornaou nad asrvsnaae cfrlla n nkuehrnp at
optpe n .peeg htsoeacpM jr Urse Tvbitfarlrtycyyxomuoi.sS aaoeuroe.a r nhsoot
ea7si Tion ,cty2S ec vd$s 3a4 rf ol5ext&hebb Pm 0oh 0dhauey5 Lt6eidy a enhe7%mea9 a.eglnns2a %.waeiTesvhlho05l cl;p1 l. id6
Please enable JavaScript to view this content.
A woman in our neighborhood claims she has been using a knock-off version of Mounjaro for several months and is seeing great results (she does look as though she has lost some weight). She buys the supply from “a guy she knows” and meets him in a parking lot once a month. Interestingly, this same woman refused to get a COVID vaccination because “I have no idea what is in the vaccine.” To top it all off, she has spent most of her professional career in pharma sales.
Lilly is charging over $13,000 per year for a life changing drug that most insurance plans won’t cover yet at the same time clamping down on a safe option that is available and while not cheap is affordable for most.
Who paid for the development of that drug? They are owed the opportunity to cover that cost and then make a profit, as well as protect their R&D. That is how businesses are run. We should be thankful companies like Lilly exist so R&D continues to fight illness.
There are patents for a reason. Why should someone be able to make a knock-off to capitalize on years and hundreds of millions of dollars spent by the developer? Then who would ever do that kind of research?
Lilly’s actions in filing lawsuits against businesses selling unapproved compounded versions of Mounjaro are in line with the need to protect public health, uphold regulatory standards, and defend intellectual property rights. These actions serve the interests of both the company and the patients who rely on safe and effective medications.
Furthermore, state laws often require that drugs comply with FDA regulations, and violating these laws can have serious consequences, why aren’t the states enforcing their own state laws for the benefit of public safety, or just do away with the laws.
It is crucial to strike a balance between the need for rigorous drug regulation and the necessity of ensuring access to essential medications. Instead of resorting to legal action, Lilly could explore alternative ways to collaborate with compounding pharmacies to ensure that patients who genuinely require Mounjaro can access it safely while maintaining FDA standards. This approach would better serve both patient well-being and public health interests.
Ultimately, Lilly’s actions highlight the complex and delicate balance between regulatory compliance and patient access to vital medications. A more nuanced approach that considers the needs of patients who rely on compounded drugs may be a more constructive way forward.